Drug Profile
Cromafiban
Alternative Names: CT 50352Latest Information Update: 29 Jun 2006
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class Antiplatelets
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris; Myocardial infarction; Stroke
Most Recent Events
- 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
- 15 Sep 1999 CT 50352 is now known as cromafiban
- 15 Sep 1999 Phase-II clinical trials for Angina pectoris in USA (PO)